The "yes" from the European Parliament to the reform of pharmaceutical legislation jeopard... 12/04/2024 We consider that improvements have been made regarding the original proposal, but these continue to be insufficient for... AseBio
Biotechnology seeks solutions for Parkinson's, the second most common neurodegenerative di... 11/04/2024 Healthcare Access to innovation Drug discovery Innovative drugs Personalized medicine Advanced therapies Parkinson's is an extremely debilitating disease, there is no cure, and we only have medications aimed at alleviating... AseBio
Biotechnology seeks solutions for Parkinson's, the second most common neurodegenerative di... 11/04/2024 Approximately 10,000 new cases of Parkinson's are detected each year in Spain, with a total figure exceeding 150,000... AseBio
Biotechnology lays the groundwork for the present and future of healthcare and drives the ... 07/04/2024 Healthcare Drug discovery Rare diseases Personalized medicine Advanced therapies Antibiotic resistance Climate change Agrifood Animal health The health pipeline of AseBio includes 130 molecules for 150 indications being investigated by 40 national companies... AseBio
Biotechnology lays the groundwork for the present and future of healthcare and drives the ... 07/04/2024 AseBio's health pipeline includes 130 molecules for 150 indications being researched by 40 national companies, with... AseBio
Celtarys Research, USC-biofarma and ZeClinics seek new therapeutic targets for Parkinson's... 01/04/2024 Healthcare Access to innovation Drug discovery Innovative drugs Advanced therapies This project, coordinated by Asebio, brings together ZeClinics' target validation and in vivo drug screening... AseBio
A consortium led by Hemostatics receives €2.5 M to validate a revolutionary therapy agains... 25/03/2024 Healthcare Advanced therapies A public-private consortium, led by the Spanish biotech company Hemostatics, located in the Barcelona Science Park, and... Partners - Parc Científic de Barcelona
Almirall signs licensing agreement with Eloxx Pharmaceuticals and enters the field of rare... 25/03/2024 Healthcare Access to innovation Rare diseases Personalized medicine Advanced therapies The Spanish pharmaceutical company has obtained global rights to develop and commercialize the drug ZKN-013. Partners - Almirall
The commercial corporation of advanced therapies, an opportunity to leverage Spanish devel... 14/03/2024 Healthcare Advanced therapies The Spanish biotech industry is present throughout the value chain of advanced therapy development and manufacturing... AseBio
The commercial corporation of advanced therapies, an opportunity to leverage Spanish devel... 14/03/2024 With the creation of this commercial corporation, it is expected to "bring two advanced therapies to authorization and... AseBio
